Kancera acquires iNovacia


Kancera AB (publ) announces that the acquisition of iNovacia AB has been implemented


About Kancera AB (publ)
Kancera AB is a biotechnology company focusing on new and effective drugs for treating leukemia and solid tumors.

About iNovacia AB
iNovacia  originates from Pharmacia’s and Biovitrum’s drug discovery. During the period of 1995-2001 Pharmacia invested in a unit for the rational development of patented drug candidates. Following the Biovitrum spin off from Pharmacia in 2001 this industrial pharmaceutical laboratory was developed further. Additional investments in instrumentation and chemical libraries were made in connection with the spin-off of iNovacia from Biovitrum in 2006. iNovacia has delivered more than 30 projects on behalf of established pharmaceutical companies in Europe and the USA. iNovacia consists of three line functions, molecular pharmacology, medicinal chemistry and analytical chemistry. iNovacia has its headquarters in Stockholm and currently employs 20 people of whom 10 are PhD.

Strengths at iNovacia:
• A hand-picked and specially designed chemical library, consisting of more than 280,000 drug compatible substances, that is validated by international pharmaceutical and biotech customers.
• Over 20 years experience in design and implementation of drug discovery projects have resulted in know-how that paves the way for development programs of high clinical importance and technical complexity.

• A broad range of physiochemical and biophysical techniques that provide an early understanding of the series of compounds that have the best chance of success in the further development towards clinical trials and how these substances can be optimized to generate a powerful drug candidate.